<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2208">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01548768</url>
  </required_header>
  <id_info>
    <org_study_id>AAAI1026</org_study_id>
    <secondary_id>7R01AR050026-07</secondary_id>
    <nct_id>NCT01548768</nct_id>
  </id_info>
  <brief_title>RHYTHM (Formerly Escape II Myocardium)</brief_title>
  <acronym>RHYTHM</acronym>
  <official_title>RHYTHM (RHeumatoid Arthritis studY of THe Myocardium): How Rheumatoid Arthritis (RA) and Tumor Necrosis Factor (TNF) Inhibitors Affect the Myocardial Structure and Function.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For aim 1, the proposed studies will be performed in 150 patients with RA and 25 subjects&#xD;
      without RA (healthy volunteers) who will function as controls.&#xD;
&#xD;
      For aim 2, 25 of the patients enrolled in aim 1 (who are in need for further treatment due to&#xD;
      increased RA activity despite their current treatment) will be recruited to continue in the&#xD;
      study for an additional 24 (+/- 2) weeks (or 6 months). These patient will receive a TNF&#xD;
      inhibitor in addition to their current treatment in an open label protocol for increased&#xD;
      disease activity and in the context of standard of care.&#xD;
&#xD;
      The investigators hypothesize that anti-TNF agents in RA patients without heart disease will&#xD;
      not adversely affect the heart (will not cause a detrimental change in heart structure or its&#xD;
      function).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with Rheumatoid Arthritis (RA) have a shortened life expectancy compared to the&#xD;
      general population. Cardiovascular disease (CVD), including heart failure (HF), is the&#xD;
      primary cause of the extra deaths in RA. HF, in general, results from failure of the heart&#xD;
      muscle to pump adequately. In other words the heart muscle in HF becomes &quot;weak&quot;. In patients&#xD;
      without RA, the heart muscle gets larger before symptoms of HF appear. Contrary to that,&#xD;
      patients with RA have reduced heart size and reduced heart strength. This may mean that in RA&#xD;
      the pathway to heart failure may be different compared to what happens in patients without&#xD;
      RA. It is possible - for example - that in RA the heart muscle becomes smaller before it&#xD;
      becomes weak (while in non-RA patients the heart muscle becomes larger before it becomes&#xD;
      weak). It is possible that cells that create inflammation in the joints may also do the same&#xD;
      in the heart muscle making it smaller, thinner and eventually weaker.&#xD;
&#xD;
      Patients with RA nowadays can be treated with a variety of medications for their joint&#xD;
      inflammation. These medications are powerful and have reduced the risk of permanent joint&#xD;
      damage and disability. However it is unknown what is the effect of these medications on the&#xD;
      heart size and strength and whether they increase or decrease the risk for cardiovascular&#xD;
      disease and heart failure.&#xD;
&#xD;
      Among the medications used for RA are medications called TNF inhibitors. They are usually&#xD;
      prescribed to patients who have joint inflammation that has not responded to treatment with&#xD;
      the first line medication Methotrexate. Data in non-RA patients with advanced heart failure&#xD;
      suggest that anti-TNF agents may not help heart failure and may even be harmful. However, the&#xD;
      effect of these agents on the hearts of RA patients has never been directly studied. Some&#xD;
      observational studies suggest that RA patients treated with TNF inhibitors have a lower risk&#xD;
      of developing heart disease. Overall the knowledge regarding the effect of TNF inhibitors on&#xD;
      RA patients heart function is limited.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 10, 2011</start_date>
  <completion_date type="Actual">September 2019</completion_date>
  <primary_completion_date type="Actual">September 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Myocardial FDG Uptake</measure>
    <time_frame>Baseline</time_frame>
    <description>This is designed to evaluate the baseline characteristics of the cross sectional RA cohort to understand the correlation of disease activity measured by the Clinical Disease Activity Index (CDAI) with myocardial inflammation measured by fluorodeoxyglucose (FDG) uptake in positron emission tomography (PET) scan at the baseline visit. Myocardial FDG uptake is classified as &quot;diffuse&quot; or &quot;focal.&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial FDG Uptake After Escalation of RA Pharmacotherapy</measure>
    <time_frame>Baseline, 6-Month Follow-up</time_frame>
    <description>This is designed to measure the myocardial inflammation, and its association with change in CDAI, after ramp-up of RA therapy over 6 months. Measurements are taken at baseline and 6-months post treatment escalation. Myocardial FDG uptake is classified as &quot;diffuse&quot; or &quot;focal.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV Structure (Mean EDVI) in Association With Myocardial FDG Uptake</measure>
    <time_frame>Baseline</time_frame>
    <description>This is designed to evaluate the baseline characteristics of the entire RA cohort to understand the association of myocardial inflammation measure by FDG uptake with measures of left ventricular (LV) structure measured by 2D/3D echocardiogram at the baseline visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV Function (Mean Stroke Volume Index) in Association With Myocardial FDG Uptake</measure>
    <time_frame>Baseline</time_frame>
    <description>This is designed to evaluate the baseline characteristics of the entire RA cohort to understand the association of myocardial inflammation measure by FDG uptake with measures of left ventricular (LV) function measured by 2D/3D echocardiogram at the baseline visit.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">149</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Patients - DMARDs + TNF Inhibitors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a TNF inhibitor in addition to their current treatment in an open label protocol for increased disease activity and in the context of standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients - DMARDs only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive their current treatment in an open label protocol in the context of standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects without RA who will function as controls.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TNF inhibitors</intervention_name>
    <description>TNF inhibitors are an FDA approved class of medications indicated for the treatment of RA when initial treatment (usually with methotrexate) has failed to achieve remission of RA disease activity. TNF inhibitors are part of the standard of care management of RA.&#xD;
The possible TNF inhibitors are: Remicade, Humira, Enbrel, Cimzia, Simponi.</description>
    <arm_group_label>Patients - DMARDs + TNF Inhibitors</arm_group_label>
    <other_name>Anti-TNF drugs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DMARDs</intervention_name>
    <description>Standard of care treatment for RA, such as Methotrexate or other disease-modifying antirheumatic drugs.</description>
    <arm_group_label>Patients - DMARDs + TNF Inhibitors</arm_group_label>
    <arm_group_label>Patients - DMARDs only</arm_group_label>
    <other_name>Disease-modifying antirheumatic drugs</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For RA patients (150 patients):&#xD;
&#xD;
        INCLUSION CRITERIA&#xD;
&#xD;
          -  Diagnosis of Rheumatoid Arthritis by 2010 American College of Rheumatology (ACR) and&#xD;
             the European League Against Rheumatism (EULAR) diagnostic criteria&#xD;
&#xD;
          -  Age&gt;18 years old&#xD;
&#xD;
          -  Moderate to high RA disease activity defined by a Clinical Disease Activity Index&#xD;
             (CDAI) of &gt;10&#xD;
&#xD;
          -  Stable dose of Methotrexate for 6 weeks prior to enrollment&#xD;
&#xD;
          -  Stable doses of Nonsteroidal anti-inflammatory drug (NSAID) and prednisone (if already&#xD;
             taking these medications) for 2 weeks prior to study&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          -  Prior self reported or physician diagnosed CV event (MI; angina; stroke or Transient&#xD;
             Ischemic Attach (TIA); Heart Failure (HF); prior CV procedure (e.g., coronary artery&#xD;
             bypass graft, angioplasty, valve replacement, pacemaker)&#xD;
&#xD;
          -  Contraindications to having a PET-CT scan or receive adenosine or Fludeoxyglucose&#xD;
             (FDG)&#xD;
&#xD;
          -  Active treatment for Cancer&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Treatment with a TNF inhibitor or other biologic currently or within the last 6 months&#xD;
&#xD;
          -  Current treatment with &quot;Triple Therapy&quot; or within the last 2 months&#xD;
&#xD;
          -  Untreated positive purified protein derivative (PPD) tuberculosis skin test or active&#xD;
             tuberculosis&#xD;
&#xD;
          -  History of Lymphoma and Melanoma&#xD;
&#xD;
          -  Ejection Fraction (EF) &lt; 40% (if not known in advance then the Study Visit I&#xD;
             Echocardiogram results will be used to exclude the patient from randomization and&#xD;
             follow up)&#xD;
&#xD;
          -  Change in NSAID/Prednisone dosage in last 2 weeks&#xD;
&#xD;
          -  Participation in other research studies involving imaging/radiation exposure&#xD;
&#xD;
        For non-RA subjects (25 controls):&#xD;
&#xD;
        INCLUSION CRITERIA&#xD;
&#xD;
          -  Age&gt;18 years old&#xD;
&#xD;
          -  Absence of diagnosis of RA&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          -  Prior self reported or physician diagnosed CV event (MI; angina; stroke or Transient&#xD;
             Ischemic Attach (TIA); Heart Failure (HF); prior CV procedure (e.g., coronary artery&#xD;
             bypass graft, angioplasty, valve replacement, pacemaker)&#xD;
&#xD;
          -  Contraindications to having a PET-CT scan or receive adenosine or FDG&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Participation in other research studies involving imaging/radiation exposure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joan M Bathon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.rheumatologyatcolumbia.org/</url>
    <description>Click here for information about this study</description>
  </link>
  <results_reference>
    <citation>Amigues I, Tugcu A, Russo C, Giles JT, Morgenstein R, Zartoshti A, Schulze C, Flores R, Bokhari S, Bathon JM. Myocardial Inflammation, Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography With Computed Tomography, Is Associated With Disease Activity in Rheumatoid Arthritis. Arthritis Rheumatol. 2019 Apr;71(4):496-506. doi: 10.1002/art.40771. Epub 2019 Feb 28.</citation>
    <PMID>30407745</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 6, 2012</study_first_submitted>
  <study_first_submitted_qc>March 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2012</study_first_posted>
  <results_first_submitted>September 21, 2020</results_first_submitted>
  <results_first_submitted_qc>November 4, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 27, 2020</results_first_posted>
  <last_update_submitted>November 4, 2020</last_update_submitted>
  <last_update_submitted_qc>November 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Joan M. Bathon</investigator_full_name>
    <investigator_title>Professor Medicine, Rheumatology</investigator_title>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Cardiovascular disease</keyword>
  <keyword>Myocardium</keyword>
  <keyword>TNF-alpha inhibitors</keyword>
  <keyword>ESCAPE</keyword>
  <keyword>Co-morbidities</keyword>
  <keyword>RHYTHM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tumor Necrosis Factor Inhibitors</mesh_term>
    <mesh_term>Antirheumatic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 19, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT01548768/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Patients - DMARDs + TNF Inhibitors</title>
          <description>Patients will receive a TNF inhibitor in addition to their current treatment in an open label protocol for increased disease activity and in the context of standard of care.&#xD;
TNF inhibitors: TNF inhibitors are an FDA approved class of medications indicated for the treatment of RA when initial treatment (usually with methotrexate) has failed to achieve remission of RA disease activity. TNF inhibitors are part of the standard of care management of RA.&#xD;
The possible TNF inhibitors are: Remicade, Humira, Enbrel, Cimzia, Simponi.&#xD;
DMARDs: Standard of care treatment for RA, such as Methotrexate or other disease-modifying antirheumatic drugs.</description>
        </group>
        <group group_id="P2">
          <title>Patients - DMARDs Only</title>
          <description>Patients will receive their current treatment in an open label protocol in the context of standard of care.&#xD;
DMARDs: Standard of care treatment for RA, such as Methotrexate or other disease-modifying antirheumatic drugs.</description>
        </group>
        <group group_id="P3">
          <title>Healthy Volunteers</title>
          <description>Subjects without RA who will function as controls.</description>
        </group>
        <group group_id="P4">
          <title>Patients - Cross Sectional (RA)</title>
          <description>A cohort of patients with Rheumatoid Arthritis will undergo the baseline study visit only (no randomization to treatment). Note, that those who were randomized, their data will be utilized in the full cross sectional analysis.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="121"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>RA participants=133, Healthy Volunteers=16</population>
      <group_list>
        <group group_id="B1">
          <title>Patients - DMARDs + TNF Inhibitors</title>
          <description>Patients will receive a TNF inhibitor in addition to their current treatment in an open label protocol for increased disease activity and in the context of standard of care.&#xD;
TNF inhibitors: TNF inhibitors are an FDA approved class of medications indicated for the treatment of RA when initial treatment (usually with methotrexate) has failed to achieve remission of RA disease activity. TNF inhibitors are part of the standard of care management of RA.&#xD;
The possible TNF inhibitors are: Remicade, Humira, Enbrel, Cimzia, Simponi.&#xD;
DMARDs: Standard of care treatment for RA, such as Methotrexate or other disease-modifying antirheumatic drugs.</description>
        </group>
        <group group_id="B2">
          <title>Patients - DMARDs Only</title>
          <description>Patients will receive their current treatment in an open label protocol in the context of standard of care.&#xD;
DMARDs: Standard of care treatment for RA, such as Methotrexate or other disease-modifying antirheumatic drugs.</description>
        </group>
        <group group_id="B3">
          <title>Healthy Volunteers</title>
          <description>Subjects without RA who will function as controls.</description>
        </group>
        <group group_id="B4">
          <title>Patients - Cross Sectional (RA)</title>
          <description>A cohort of patients with Rheumatoid Arthritis will undergo the baseline study visit only (no randomization to treatment). Note, that those who were randomized, their data will be utilized in the full cross sectional analysis.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="121"/>
            <count group_id="B5" value="149"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="105"/>
                    <measurement group_id="B5" value="130"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.125" lower_limit="32" upper_limit="64"/>
                    <measurement group_id="B2" value="56" lower_limit="26" upper_limit="70"/>
                    <measurement group_id="B3" value="52" lower_limit="28" upper_limit="68"/>
                    <measurement group_id="B4" value="55.6" lower_limit="23" upper_limit="80"/>
                    <measurement group_id="B5" value="54.38" lower_limit="23" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="105"/>
                    <measurement group_id="B5" value="127"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B5" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="69"/>
                    <measurement group_id="B5" value="89"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Myocardial FDG Uptake</title>
        <description>This is designed to evaluate the baseline characteristics of the cross sectional RA cohort to understand the correlation of disease activity measured by the Clinical Disease Activity Index (CDAI) with myocardial inflammation measured by fluorodeoxyglucose (FDG) uptake in positron emission tomography (PET) scan at the baseline visit. Myocardial FDG uptake is classified as &quot;diffuse&quot; or &quot;focal.&quot;</description>
        <time_frame>Baseline</time_frame>
        <population>2 RA patients and 1 healthy volunteer (control subject) were not included in this analysis population because the subjects withdrew study participation prior to scan (no data were collected).</population>
        <group_list>
          <group group_id="O1">
            <title>Patients - Cross Sectional (RA)</title>
            <description>A cohort of patients with Rheumatoid Arthritis who underwent the baseline visit analysis and completed the visit in the full cross sectional analysis.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Volunteers</title>
            <description>A cohort of healthy volunteers (those without an autoimmune or history of cardiac illness) was utilized. n=16 were recruited directly, while n=11 were recruited via the CUIMC Nuclear Cardiology archive.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Myocardial FDG Uptake</title>
          <description>This is designed to evaluate the baseline characteristics of the cross sectional RA cohort to understand the correlation of disease activity measured by the Clinical Disease Activity Index (CDAI) with myocardial inflammation measured by fluorodeoxyglucose (FDG) uptake in positron emission tomography (PET) scan at the baseline visit. Myocardial FDG uptake is classified as &quot;diffuse&quot; or &quot;focal.&quot;</description>
          <population>2 RA patients and 1 healthy volunteer (control subject) were not included in this analysis population because the subjects withdrew study participation prior to scan (no data were collected).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diffuse FDG Uptake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Focal FDG Uptake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No FDG Uptake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial FDG Uptake After Escalation of RA Pharmacotherapy</title>
        <description>This is designed to measure the myocardial inflammation, and its association with change in CDAI, after ramp-up of RA therapy over 6 months. Measurements are taken at baseline and 6-months post treatment escalation. Myocardial FDG uptake is classified as &quot;diffuse&quot; or &quot;focal.&quot;</description>
        <time_frame>Baseline, 6-Month Follow-up</time_frame>
        <population>2 TNFi, and 2 DMARDs and 1 healthy volunteer (control subject) were not included in this analysis population because the subjects withdrew participation prior to study completion or scan (no data were collected).</population>
        <group_list>
          <group group_id="O1">
            <title>RA Patients - Pharmacotherapy Escalation (TNFi)</title>
            <description>Participants were randomized to TNFi or DMARD therapy.&#xD;
Patients will receive their current treatment in an open label protocol in the context of standard of care.&#xD;
TNFi: biologic treatment for RA, such as Humira, Enbrel, Remicade,</description>
          </group>
          <group group_id="O2">
            <title>RA Patients - Pharmacotherapy Escalation (DMARD)</title>
            <description>Participants were randomized to TNFi or DMARD therapy.&#xD;
Patients will receive their current treatment in an open label protocol in the context of standard of care.&#xD;
DMARDs: Standard of care treatment for RA, such as Methotrexate or other disease-modifying antirheumatic drugs.</description>
          </group>
          <group group_id="O3">
            <title>Healthy Volunteers</title>
            <description>A cohort of healthy volunteers (those without an autoimmune or history of cardiac illness) was utilized. n=16 were recruited directly, while n=11 were recruited via the CUIMC Nuclear Cardiology archive.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Myocardial FDG Uptake After Escalation of RA Pharmacotherapy</title>
          <description>This is designed to measure the myocardial inflammation, and its association with change in CDAI, after ramp-up of RA therapy over 6 months. Measurements are taken at baseline and 6-months post treatment escalation. Myocardial FDG uptake is classified as &quot;diffuse&quot; or &quot;focal.&quot;</description>
          <population>2 TNFi, and 2 DMARDs and 1 healthy volunteer (control subject) were not included in this analysis population because the subjects withdrew participation prior to study completion or scan (no data were collected).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Focal Baseline FDG Uptake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Focal Follow-up FDG Uptake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="NA">Healthy Controls were not re-scanned 6-months later, and served as a comparison marker</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diffuse Baseline FDG Uptake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diffuse Follow-up FDG Uptake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="NA">Healthy Controls were not re-scanned 6-months later, and served as a comparison marker</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LV Structure (Mean EDVI) in Association With Myocardial FDG Uptake</title>
        <description>This is designed to evaluate the baseline characteristics of the entire RA cohort to understand the association of myocardial inflammation measure by FDG uptake with measures of left ventricular (LV) structure measured by 2D/3D echocardiogram at the baseline visit.</description>
        <time_frame>Baseline</time_frame>
        <population>Only 119 out of 121 subjects had data analyzed due to 2 subject withdrawals prior to scan.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients - Cross Sectional (RA)</title>
            <description>A cohort of patients with Rheumatoid Arthritis who underwent the baseline visit analysis and completed the visit in the full cross sectional analysis.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Volunteers</title>
            <description>A cohort of healthy volunteers (those without an autoimmune or history of cardiac illness) was utilized. n=16 were recruited directly, while n=11 were recruited via the CUIMC Nuclear Cardiology archive</description>
          </group>
        </group_list>
        <measure>
          <title>LV Structure (Mean EDVI) in Association With Myocardial FDG Uptake</title>
          <description>This is designed to evaluate the baseline characteristics of the entire RA cohort to understand the association of myocardial inflammation measure by FDG uptake with measures of left ventricular (LV) structure measured by 2D/3D echocardiogram at the baseline visit.</description>
          <population>Only 119 out of 121 subjects had data analyzed due to 2 subject withdrawals prior to scan.</population>
          <units>ml/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.8" spread="11"/>
                    <measurement group_id="O2" value="49.1" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LV Function (Mean Stroke Volume Index) in Association With Myocardial FDG Uptake</title>
        <description>This is designed to evaluate the baseline characteristics of the entire RA cohort to understand the association of myocardial inflammation measure by FDG uptake with measures of left ventricular (LV) function measured by 2D/3D echocardiogram at the baseline visit.</description>
        <time_frame>Baseline</time_frame>
        <population>Only 119 out of 121 subjects had data analyzed due to 2 subject withdrawals prior to scan.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients - Cross Sectional (RA)</title>
            <description>A cohort of patients with Rheumatoid Arthritis who underwent the baseline visit analysis and completed the visit in the full cross sectional analysis.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Volunteers</title>
            <description>A cohort of healthy volunteers (those without an autoimmune or history of cardiac illness) was utilized. n=16 were recruited directly, while n=11 were recruited via the CUIMC Nuclear Cardiology archive</description>
          </group>
        </group_list>
        <measure>
          <title>LV Function (Mean Stroke Volume Index) in Association With Myocardial FDG Uptake</title>
          <description>This is designed to evaluate the baseline characteristics of the entire RA cohort to understand the association of myocardial inflammation measure by FDG uptake with measures of left ventricular (LV) function measured by 2D/3D echocardiogram at the baseline visit.</description>
          <population>Only 119 out of 121 subjects had data analyzed due to 2 subject withdrawals prior to scan.</population>
          <units>ml/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6" spread="13.9"/>
                    <measurement group_id="O2" value="31.3" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For those who underwent the baseline scans only (RA cross-sectional cohort, Healthy Controls), the gathering of adverse events were determined from the events from the visit alone (either acute, or patient-reported follow-up); For the group escalated in treatment therapy (n=12), adverse events were collected from baseline visit/randomization to the end-of-study safety visit conducted 6-8 weeks after the 6-month study visit.</time_frame>
      <desc>An adverse event (AE) is any undesirable sign, symptom or medical condition occurring after starting study drug (or therapy). Medical conditions/diseases present before starting study treatment are only considered adverse events if they worsen after starting study therapy. In addition all adverse events regardless of whether they constitute unanticipated problems as well as AEs thought to be possibly related to study procedures will also be reported to IRB, safety officer, SMC, and NIH/NIAMS.</desc>
      <group_list>
        <group group_id="E1">
          <title>RA Patients - Pharmacotherapy Escalation (TNFi)</title>
          <description>Participants were randomized to TNFi or DMARD therapy. Patients will receive their current treatment in an open label protocol in the context of standard of care.&#xD;
TNFi: biologic treatment for RA, such as Humira, Enbrel, Remicade,</description>
        </group>
        <group group_id="E2">
          <title>RA Patients - Pharmacotherapy Escalation (DMARD)</title>
          <description>Participants were randomized to TNFi or DMARD therapy. Patients will receive their current treatment in an open label protocol in the context of standard of care.&#xD;
DMARDs: Standard of care treatment for RA, such as Methotrexate or other disease-modifying antirheumatic drugs.</description>
        </group>
        <group group_id="E3">
          <title>Healthy Volunteers</title>
          <description>Subjects without RA who will function as controls.</description>
        </group>
        <group group_id="E4">
          <title>Patients - Cross Sectional (RA)</title>
          <description>A cohort of patients with Rheumatoid Arthritis will undergo the baseline study visit only (no randomization to treatment). Note, that those who were randomized, their data will be utilized in the full cross sectional analysis.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness Of Breath</sub_title>
                <description>Participant was admitted during overseas travel to hospital in Ecuador for an episode of acute dyspnea - she spent one night in a hospital in Panama before returning to the US.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Mobitz II Heart Block</sub_title>
                <description>Could not tolerate adenosine - subject went into heart block (otherwise asymptomatic); IRB gave approval for regadenoson on re-try later.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Atrial Tachycardia</sub_title>
                <description>Short run of atrial tachycardia which self-reverted to normal sinus rhythm after 100mg aminophyllin. No re-occurance.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening Migraine</sub_title>
                <description>Subject w/ h/o migraine; during study visit, mild migraine in morning worsened (BP 140/69, HR 100) - given acetaminophen 500mg x2 - decision made to admit to ED for observation. Same-day discharge from ED.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Angina</sub_title>
                <description>Angina during adenosine stress test w/ ischemic ECG changes during test. Resolved on completion of test.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Panic Attack</sub_title>
                <description>Subject had panic attack during stress scan - test was aborted and not retried.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <description>Subject had swelling from IV site; prescribed Keflex for 10 days, which resolved.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <description>Subject reported new pruritic skin rash (c/w eczema on exam) on start of study medication. Study medication d/c'ed 1mnth later and initiated medrol w/ good response. Later followed up with dermatology who confirmed eczema.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Joan Bathon, MD</name_or_title>
      <organization>Columbia University Irving Medical Center</organization>
      <phone>212-305-6327</phone>
      <email>jmb2311@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

